Insmed SG&A increased by 16.4% to $247.26M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 67.6%, from $147.55M to $247.26M. Over 3 years (FY 2022 to FY 2025), SG&A shows an upward trend with a 38.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $66.45M | $66.45M | $66.45M | $66.45M | $86.13M | $86.13M | $86.13M | $86.13M | $93.10M | $106.57M | $118.93M | $142.52M | $147.55M | $154.76M | $186.38M | $212.48M | $247.26M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +29.6% | +0.0% | +0.0% | +0.0% | +8.1% | +14.5% | +11.6% | +19.8% | +3.5% | +4.9% | +20.4% | +14.0% | +16.4% |
| YoY Change | — | — | — | — | +29.6% | +29.6% | +29.6% | +29.6% | +8.1% | +23.7% | +38.1% | +65.5% | +58.5% | +45.2% | +56.7% | +49.1% | +67.6% |
Range$66.45M – $247.26M
CAGR+38.9%
Avg YoY Growth+40.8%
Median YoY Growth+38.1%
Current Streak16+ quarters growth
SG&A at Other Companies
Frequently Asked Questions
- What is Insmed's sg&a?
- Insmed (INSM) reported sg&a of $247.26M in Q1 2026.
- How has Insmed's sg&a changed year-over-year?
- Insmed's sg&a increased by 67.6% year-over-year, from $147.55M to $247.26M.
- What is the long-term trend for Insmed's sg&a?
- Over 3 years (2022 to 2025), Insmed's sg&a has grown at a 38.2% compound annual growth rate (CAGR), from $265.78M to $701.17M.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.